Material safety data sheet

Material Safety Data Sheet

Date Prepared: 10/17/03
X-Gen Pharmaceuticals
Prepared
Technical Assistance: 607-562-2700
Big Flats, NY 14814
TRIAMCINOLONE ACETONIDE
IDENTIFICATION

Common Name:
Triamcinolone Acetonide
Chemical Name: Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-
methylethylidene)bis(oxy)]-, (11beta, 16alpha)- Synonym: n/f
Formula: C24H31FO6
CAS Number: 76-25-5
RTECS Number: TU3920000
Chemical Family: Corticosteroid
Therapeutic Category: Glucocorticoid
INGREDIENT INFORMATION

Principle Components
Exposure Limits
HEALTH HAZARD INFORMATION

Usual Adult Dose:
The usual adult dose of triamcinolone acetonide is 2.5 to 100 mg given by
injection. It is also used topically in concentrations of 0.025 to 0.5%, and by inhalation up to 1600
micrograms per day.
Adverse Effects: Toxic signs and symptoms rarely occur with administration of less than 3 weeks
duration; even a massive single dose of this material is unlikely to cause adverse effects. If they do
occur, adverse effects may include decreased or blurred vision, frequent urination, increased thirst,
loss of appetite, indigestion, nervousness or restlessness, and trouble sleeping. Possible allergic
reaction to material if inhaled, ingested or in contact with skin.
Overdose Effects: n/f

Acute:
Possible eye, skin, gastrointestinal and/or respiratory tract irritation.
n/f = not found
TRIAMCINOLONE ACETONIDE
HEALTH HAZARD INFORMATION CONTINUED

Chronic:
Possible hypersensitization, acne or other skin problems, hip or shoulder pain, fullness in
face, swelling of feet or lower legs, menstrual irregularities, nausea, vomiting, irregular heartbeat,
muscle cramps, weakness, osteoporosis, increased susceptibility to infection, psychosis, and eye
problems.

Inhalation:
May cause irritation. Remove to fresh air.

Eye:
May cause irritation. Flush with copious quantities of water.

Skin:
Causes irritation and can be absorbed through the skin in sufficient quantity to cause systemic
effects. Flush with copious quantities of soap and water.

Ingestion:
May cause irritation. Flush out mouth with water.

Medical Conditions Aggravated by Exposure:
Hypersensitivity to material; ocular herpes simplex;
active alcoholism; AIDS or HIV infection; heart disease or hypertension; diabetes mellitus;
myasthenia gravis; impaired liver or kidney function; esophagitis, gastritis or peptic ulcer; chickenpox
or measles (including recent exposure); tuberculosis; and systemic fungal infections.
Cross Sensitivity: Persons hypersensitive to other corticosteroids may be hypersensitive to this
material also.
Pregnancy Comments: Although adequate and well-controlled pregnancy studies have not been
done in humans, there is some evidence that pharmacologic doses of corticosteroids may increase the
risk of placental insufficiency, decreased birth weight, or stillbirth. However, birth defects in humans
have not been confirmed. Studies in animals have shown that corticosteroids increase the incidence of
cleft palate, placental insufficiency, miscarriage, and slowed intrauterine growth.
Pregnancy Category: n/f
FIRST AID MEASURES

General: Remove from exposure. Remove contaminated clothing. Persons developing serious
hypersensitivity (anaphylactic) reactions must receive immediate medical attention. If person is not
breathing give artificial respiration. If breathing is difficult give oxygen. Obtain medical attention.
Overdose Treatment: Treatment for acute overdose is generally symptomatic and supportive;
antacids may be used to relieve gastrointestinal irritation. Psychic disturbances (which may be
delayed for up to 2 weeks following large ingestions) are treatable with a phenothiazine or lithium.
Tricyclic antidepres

Source: http://x-genpharmaceuticals.us/Powders/Triamcinolone/Triamcinolone_files/MSDS/Triamcinolone.pdf

cabinet.leicester.gov.uk

GETTING THE MOST FROM GLENVALE FEEDBACK ON THE CONSULTATION REPORT The Day Hospital Manager has made arrangements to meet with staff, service users and carers from 10th July 2003. A letter has also been prepared for service users and carers to explain that they will continue to receive a service and to ask their views about the developments. Service Users and carers will also be ab

Bill 31 submission

Submission to the Standing Committee on Community Services Bill 31: Mental Health Amendment Act I'm very concerned about the "unintentional consequences" of Bill 31. In terms of my special interest area, the collateral damage is very likely going to include an increase of both chemical and physical restraints, instead of adequate and appropriate care, for elderly persons whose dem

© 2010-2018 PDF pharmacy articles